A Form 4 filed on August 14, 2026, with the U.S. Securities and Exchange Commission discloses that Michael R. Hayden, a director of AbCellera Biologics Inc. (NASDAQ:ABCL), acquired 46,387 common shares on August 12, 2026, at a weighted-average price of $10.37 per share.

Key Highlights

  • Reporting person: Michael R. Hayden, identified as a Director of AbCellera Biologics Inc.
  • Transaction: Purchase (Code P) of 46,387 common shares on August 12, 2026.
  • Price range: Shares were acquired in multiple transactions at prices ranging from $10.25 to $10.45, with a weighted-average price of $10.37.
  • Indirect holdings after transaction: 1,319,784 common shares held indirectly through Genworks 2 Consulting, Inc.
  • Additional indirect holding: 118,245 common shares held indirectly by spouse.
  • Disclaimer: Hayden disclaims beneficial ownership of shares held by Genworks 2, except to the extent of his indirect pecuniary interest, if any.

Hayden's Share Purchase and Beneficial Ownership at AbCellera Biologics

According to the Form 4 filing, Michael R. Hayden, serving as a Director of AbCellera Biologics Inc., executed a purchase transaction on August 12, 2026. The filing reports the acquisition of 46,387 common shares at a weighted-average price of $10.37. As disclosed in a footnote, the shares were acquired in multiple transactions at prices ranging from $10.25 to $10.45, and Hayden has undertaken to provide full per-price details upon request to the issuer, any security holder, or SEC staff.

The filing reports that following the transaction, Hayden indirectly beneficially owns 1,319,784 common shares held by Genworks 2 Consulting, Inc. According to the filing, Hayden's spouse holds sole voting and investment power over the shares held by Genworks 2. The filing notes that Hayden "disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein." An additional 118,245 common shares are reported as held indirectly by spouse.

The Form 4 was signed by Tryn Stimart as attorney-in-fact and filed on August 14, 2026. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

AbCellera Biologics director Michael R. Hayden reported the purchase of 46,387 common shares on August 12, 2026, at a weighted-average price of $10.37, with indirect beneficial ownership of 1,319,784 shares through Genworks 2 Consulting, Inc. following the transaction.